FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) was founded with Axcelead Drug Discovery Partners Co., Ltd. (Headquarters: Fujisawa City, Kanagawa Prefecture, President: Yoshinori Ikeura, hereinafter Axcelead) We have signed a partnership agreement on drug support.

Under this agreement, FRONTEO and Axcelead will mutually provide their respective drug discovery support technologies and start sales cooperation for their drug discovery support services.Axcelead's technology and know-how accumulated through many years of drug discovery experience in pharmaceutical companies, vast amounts of data, and artificial intelligence "Concept Encoder (registered trademark: concept encoder)"^®, Reading: Concept Encoder) ”, FRONTEO's original drug discovery support service that combines a cognitive-bias-free artificial intelligence approach to realize a seamless hypothesis-verification process for customers. Accelerate drug discovery research.

This partnership will enable both customers to provide a set of AI-based drug discovery hypothesis building and experimental efficacy verification. By verifying the hypothesis made by FRONTEO's excellent drug discovery support AI for natural language analysis with Axcelead's drug discovery support platform and analyzing the experimental results conducted with Axcelead with AI, it has higher clinical applicability. It is possible to provide services.

Axcelead Drug Discovery PartnersLtd. Comment from Yoshinori Ikeura, President and CEO

Through this partnership, FRONTEO's unique natural language analysis AI and our drug discovery-related technology will be combined to realize an efficient hypothesis-verification process, and customer creation such as target search, drug repositioning, and action mechanism analysis. We look forward to providing new solutions in the key steps of medicine.

Comment from Hiroyoshi Toyoshiba, AI CTO, FRONTEO Inc.

This partnership is a full-scale AI drug discovery initiative that enables FRONTEO's artificial intelligence and the abundant experience and data accumulated in Axcelead to be utilized in new drug discovery research.We are confident that we can provide our customers with original services that combine natural language analysis, data at each drug discovery stage, and the abundant experience of researchers.

We anticipate that this issue alone will have a minor impact on FRONTEO's business results for the fiscal year ending March 2021, but we will promptly announce any reasons that should be disclosed in the future.

Axceleadabout URL: https://www.axcelead.com/

Axcelead is the first drug discovery solution provider in Japan that was established in July 2017 by spinning out the drug discovery platform business of Takeda Pharmaceutical Company Limited.It has almost all the functions required for drug discovery, and provides one-stop non-clinical drug discovery research services from drug discovery target search to drug candidate compound optimization to the bridging process to clinical development. ..

FRONTEOabout URL: https://www.fronteo.com/

FRONTEO is an in-house developed AI engine "KIBIT" that specializes in natural language processing.^®And "Concept Encoder"^®Is a data analysis company that supports the business of a company by extracting meaningful and important information from a huge amount of text data using. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic evidence disclosure)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we will expand the business field to the life science field and business intelligence field from 8, and use AI to "turn text data into knowledge" to support drug discovery. , Dementia diagnosis support, financial, personnel, sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).